Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Listed as NCT03629678, this NA trial focuses on Sickle Cell Disease and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 13 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Feb 2025 — Present [monthly]
Completed NA
-
Dec 2024 — Feb 2025 [monthly]
Completed NA
-
Sep 2024 — Dec 2024 [monthly]
Completed NA
-
Aug 2024 — Sep 2024 [monthly]
Completed NA
-
Jul 2024 — Aug 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Dec 2022 — Jul 2024 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Dec 2022 [monthly]
Recruiting NA
-
Jan 2021 — Dec 2021 [monthly]
Recruiting NA
-
Nov 2020 — Jan 2021 [monthly]
Recruiting NA
-
Aug 2020 — Nov 2020 [monthly]
Recruiting NA
Status: Active Not Recruiting → Recruiting
-
May 2020 — Aug 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — May 2020 [monthly]
Recruiting NA
-
Sep 2018 — Sep 2019 [monthly]
Recruiting NA
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- Ohio State University
- Vanderbilt University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .